Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Fosun Purchases Another $35 Million of Simcere’s Stock

publication date: Mar 23, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Fosun Pharma has bought another slice of Simcere Pharma, paying $35 million on the open market for slightly less than a 1% stake. The latest purchase brings their holdings to 7.5% of the company’s outstanding shares. Fosun, which has been nibbling at Simcere for some time now, has not declared any desire to acquire Simcere, but it seems only reasonable that they will eventually seek some sort of relationship. More details....

Stock Symbols: (SHE: 600196) (NYSE: SCR)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners